A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease

A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease

Abstract Background Interleukin-1 receptor 1 (IL-1R1) inhibition is a potential strategy for treating patients with chronic obstructive pulmonary disease (COPD). MEDI8968, a fully human monoclonal antibody, binds selectively to IL-1R1, inhibiting activation by IL-1α and IL-1β. We studied the efficac...

Full description

Bibliographic Details
Main Authors: Peter M. A. Calverley, Sanjay Sethi, Michelle Dawson, Christine K. Ward, Donna K. Finch, Mark Penney, Paul Newbold, René van der Merwe
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Respiratory Research
Subjects:
C-reactive protein
COPD
Fibrinogen
Interleukin-1 receptor 1
MEDI8968
Neutrophils
Online Access:http://link.springer.com/article/10.1186/s12931-017-0633-7

Internet

http://link.springer.com/article/10.1186/s12931-017-0633-7

Similar Items